Revenue growth of India's pharmaceutical sector is expected to" moderate" to 9 per cent in FY22, as compared with a healthy rise of 12.5 per cent during the previous fiscal, Crisil said. The agency attributed slower growth in exports, weak support from Covid-19 vaccine opportunities, and a slow pick-up in demand in the domestic formulations market as some of the reasons behind the possible degrowth." Operating profitability will shrink, too, by as much as 300 basis points this fiscal, due to a s
经济
商业标准报-经济和政策
2021-11-17 00:00:00.0